Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WIN-Partners CoTSE:3183 +0.38%67 PS Ratio is 0.40 as of Jul. 21, 2026, which is 13% below its 10-year median of 0.46. GuruFocus rates TSE:3183 with a GF Score™ of 67/100 and a GF Value™ of 円1,527.28 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, WIN-Partners Co ranks better than 51.28% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, WIN-Partners Co's share price is 円1306.00.
WIN-Partners Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,255.90. Hence, WIN-Partners Co's PS Ratio for today is 0.40.
The historical rank and industry rank for WIN-Partners Co's PS Ratio or its related term are showing as below:
TSE:3183'
s PS Ratio Range Over the Past 10 Years
Min: 0.34 Med: 0.46 Max: 0.9
Current: 0.4
During the past 13 years, WIN-Partners Co's highest PS Ratio was 0.90. The lowest was 0.34. And the median was 0.46.
TSE:3183's PS Ratio is ranked better than 51.28% of 117
companies
in the Medical Distribution industry
Industry Median: 0.4
vs TSE:3183: 0.40
During the past 12 months, the average Revenue per Share Growth Rate of WIN-Partners Co was 15.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 8.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.50% per year.
During the past 13 years, WIN-Partners Co's highest 3-Year average Revenue per Share Growth Rate was 16.60% per year. The lowest was -77.00% per year. And the median was 5.80% per year.
Back to Basics: PS Ratio
WIN-Partners Co (TSE:3183) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
WIN-Partners Co PS Ratio Related Terms
WIN-Partners Co PS Ratio Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, WIN-Partners Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
WIN-Partners Co's Share Price of today is 円1306.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WIN-Partners Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円3,255.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
WIN-Partners Co (TSE:3183) has a PS Ratio of 0.40 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on WIN-Partners Co and its competitors. This is 13% below median its historical median of 0.46. Over the past decade, WIN-Partners Co's PS Ratio has ranged from 0.34 to 0.90. According to the industry distribution chart, WIN-Partners Co ranks #57 out of 117 companies in the Medical Distribution industry, placing it in the top 48.7%.
Is WIN-Partners Co's PS Ratio too high?
WIN-Partners Co's current PS Ratio of 0.40 is 13% below median its 10-year median of 0.46. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 0.90. The Medical Distribution industry median PS Ratio is 0.40. WIN-Partners Co's value of 0.40 is 0% at this industry median. Based on the distribution chart, WIN-Partners Co ranks #57 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, WIN-Partners Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's PS Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #57 out of 117 companies for PS Ratio. This puts WIN-Partners Co in the upper half of its industry. The industry median PS Ratio is 0.40. WIN-Partners Co's value of 0.40 is 0% at this benchmark. Historically, WIN-Partners Co's own PS Ratio has ranged from 0.34 to 0.90 over the past decade. While the company's 10-year median is 0.46 vs. the industry median of 0.40, WIN-Partners Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.40, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current PS Ratio of 0.40 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on WIN-Partners Co and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current PS Ratio is 0.40, which is 13% below median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,527.28, compared to a current price of 円1,306.00 — trading 14.5% below its estimated fair value. The current PS Ratio is 0.40, which is 13% below median its 10-year median of 0.46 and 0% at the Medical Distribution industry median of 0.40. WIN-Partners Co's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current PS Ratio is 0.40 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,306.00 is trading 14.5% below its estimated GF Value™ of 円1,527.28.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
PS Ratio: 0.40 (13% below median its 10-year median of 0.46)
GF Value™: 円1,527.28 vs. price of 円1,306.00 (14.5% below fair value)
Industry Position: 0% at the Medical Distribution median (#57 of 117)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
67GF Score
Get the complete analysis for TSE:3183
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
